• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

人类羰基还原酶3(CBR3)天然等位基因变体的功能意义

Functional significance of a natural allelic variant of human carbonyl reductase 3 (CBR3).

作者信息

Lakhman Sukhwinder S, Ghosh Debashis, Blanco Javier G

机构信息

Department of Pharmaceutical Sciences, The State University of New York at Buffalo, 545 Cooke Hall, Buffalo, NY 14260-1200, USA.

出版信息

Drug Metab Dispos. 2005 Feb;33(2):254-7. doi: 10.1124/dmd.104.002006. Epub 2004 Nov 10.

DOI:10.1124/dmd.104.002006
PMID:15537833
Abstract

Human carbonyl reductase (CBR) activity accounts for a significant fraction of the metabolism of endogenous and xenobiotic carbonyl compounds. It is possible that genetic polymorphisms in CBR1 and CBR3 are key for the wide interindividual variability in the disposition of CBR drug substrates. We pinpointed a single nucleotide polymorphism in CBR3 (CBR3 V244M) that encodes for a V244 to M244 change. Blacks showed a higher frequency of the M244 allele (q = 0.51, n = 49) than did whites (q = 0.31, n = 70; p = 0.003). In addition, DNA variation panels from 10 ethnic groups presented a wide range of CBR3 V244M genotype distributions. Kinetic experiments with the recombinant CBR3 protein variants and menadione revealed that CBR3 M244 has significantly higher V(max) than does CBR3 V244 (V(max) CBR3 M244 = 40.6 +/- 1.3 micromol/min x mg versus V(max) CBR3 V244 = 19.6 +/- 2.0 micromol/min x mg, p = 0.002). In contrast, both isoforms presented similar K(m) values (K(m) CBR3 M244 = 22.9 +/- 2.9 microM versus K(m) CBR3 V244 = 24.6 +/- 3.2 microM, p = 0.43). Assays with NADP(H) demonstrated a higher V(maxNADP(H)) (1.6-fold) and increased catalytic efficiency (V(maxNADP(H))/K(mNADP(H))) for CBR3 M244 compared with CBR3 V244 (p = 0.013). Comparative three-dimensional analyses based on the structure of the homologous porcine carbonyl reductase suggested that the V244M substitution is positioned in a region critical for interactions with the NADP(H) cofactor. These studies demonstrate that the common CBR3 V244M polymorphism encodes for CBR3 isoforms with distinctive enzymatic properties.

摘要

人类羰基还原酶(CBR)活性在内源性和外源性羰基化合物的代谢中占很大一部分。CBR1和CBR3中的基因多态性可能是CBR药物底物处置中个体间广泛差异的关键。我们确定了CBR3中的一个单核苷酸多态性(CBR3 V244M),它编码V244到M244的变化。黑人中M244等位基因的频率(q = 0.51,n = 49)高于白人(q = 0.31,n = 70;p = 0.003)。此外,来自10个种族群体的DNA变异面板呈现出广泛的CBR3 V244M基因型分布。用重组CBR3蛋白变体和甲萘醌进行的动力学实验表明,CBR3 M244的V(max)显著高于CBR3 V244(CBR3 M244的V(max)= 40.6 +/- 1.3微摩尔/分钟×毫克,而CBR3 V244的V(max)= 19.6 +/- 2.0微摩尔/分钟×毫克,p = 0.002)。相比之下,两种同工型呈现出相似的K(m)值(CBR3 M244的K(m)= 22.9 +/- 2.9微摩尔,而CBR3 V244的K(m)= 24.6 +/- 3.2微摩尔,p = 0.43)。用NADP(H)进行的测定表明,与CBR3 V244相比,CBR3 M244的V(maxNADP(H))更高(高1.6倍),催化效率(V(maxNADP(H))/K(mNADP(H)))增加(p = 0.013)。基于同源猪羰基还原酶结构的比较三维分析表明,V244M取代位于与NADP(H)辅因子相互作用的关键区域。这些研究表明,常见的CBR3 V244M多态性编码具有独特酶学性质的CBR3同工型。

相似文献

1
Functional significance of a natural allelic variant of human carbonyl reductase 3 (CBR3).人类羰基还原酶3(CBR3)天然等位基因变体的功能意义
Drug Metab Dispos. 2005 Feb;33(2):254-7. doi: 10.1124/dmd.104.002006. Epub 2004 Nov 10.
2
Genetic polymorphisms in the carbonyl reductase 3 gene CBR3 and the NAD(P)H:quinone oxidoreductase 1 gene NQO1 in patients who developed anthracycline-related congestive heart failure after childhood cancer.儿童癌症后发生蒽环类药物相关充血性心力衰竭患者的羰基还原酶3基因(CBR3)和NAD(P)H:醌氧化还原酶1基因(NQO1)中的基因多态性。
Cancer. 2008 Jun 15;112(12):2789-95. doi: 10.1002/cncr.23534.
3
Anthracycline-related cardiomyopathy after childhood cancer: role of polymorphisms in carbonyl reductase genes--a report from the Children's Oncology Group.蒽环类药物相关的儿童期癌症后心肌病:羰基还原酶基因多态性的作用——来自儿童肿瘤学组的报告。
J Clin Oncol. 2012 May 1;30(13):1415-21. doi: 10.1200/JCO.2011.34.8987. Epub 2011 Nov 28.
4
Naturally occurring variants of human aldo-keto reductases with reduced in vitro metabolism of daunorubicin and doxorubicin.具有降低柔红霉素和阿霉素体外代谢能力的人醛酮还原酶的天然变异体。
J Pharmacol Exp Ther. 2010 Dec;335(3):533-45. doi: 10.1124/jpet.110.173179. Epub 2010 Sep 13.
5
Analysis of the substrate-binding site of human carbonyl reductases CBR1 and CBR3 by site-directed mutagenesis.通过定点诱变分析人羰基还原酶CBR1和CBR3的底物结合位点。
Chem Biol Interact. 2009 Mar 16;178(1-3):234-41. doi: 10.1016/j.cbi.2008.11.004. Epub 2008 Nov 18.
6
A functional genetic polymorphism on human carbonyl reductase 1 (CBR1 V88I) impacts on catalytic activity and NADPH binding affinity.人类羰基还原酶1上的一个功能性基因多态性(CBR1 V88I)影响催化活性和NADPH结合亲和力。
Drug Metab Dispos. 2007 Jun;35(6):973-80. doi: 10.1124/dmd.107.014779. Epub 2007 Mar 7.
7
CBR3 V244M is associated with LVEF reduction in breast cancer patients treated with doxorubicin.CBR3 V244M与接受阿霉素治疗的乳腺癌患者左心室射血分数降低有关。
Cardiooncology. 2021 May 11;7(1):17. doi: 10.1186/s40959-021-00103-0.
8
Importance of the substrate-binding loop region of human monomeric carbonyl reductases in catalysis and coenzyme binding.人单体羰基还原酶的底物结合环区域在催化作用和辅酶结合中的重要性。
Life Sci. 2009 Aug 12;85(7-8):303-8. doi: 10.1016/j.lfs.2009.06.005. Epub 2009 Jun 23.
9
Naturally occurring variants of human CBR3 alter anthracycline in vitro metabolism.人类 CBR3 的自然发生变体改变蒽环类药物的体外代谢。
J Pharmacol Exp Ther. 2010 Mar;332(3):755-63. doi: 10.1124/jpet.109.160614. Epub 2009 Dec 9.
10
CBR1 and CBR3 pharmacogenetics and their influence on doxorubicin disposition in Asian breast cancer patients.CBR1和CBR3的药物遗传学及其对亚洲乳腺癌患者阿霉素处置的影响。
Cancer Sci. 2008 Oct;99(10):2045-54. doi: 10.1111/j.1349-7006.2008.00903.x.

引用本文的文献

1
Genes of Predisposition to Childhood Beta-Cell Acute Lymphoblastic Leukemia in the Kazakh Population.哈萨克族儿童急性 B 淋巴细胞白血病易感性相关基因。
Asian Pac J Cancer Prev. 2023 Aug 1;24(8):2653-2666. doi: 10.31557/APJCP.2023.24.8.2653.
2
Role of Pharmacogenetics in the Treatment of Acute Myeloid Leukemia: Systematic Review and Future Perspectives.药物遗传学在急性髓系白血病治疗中的作用:系统评价与未来展望
Pharmaceutics. 2022 Mar 3;14(3):559. doi: 10.3390/pharmaceutics14030559.
3
Inter-Individual Variation and Cardioprotection in Anthracycline-Induced Heart Failure.
蒽环类药物所致心力衰竭中的个体间差异与心脏保护作用
J Clin Med. 2021 Sep 9;10(18):4079. doi: 10.3390/jcm10184079.
4
Use of hiPSC to explicate genomic predisposition to anthracycline-induced cardiotoxicity.利用 hiPSC 阐明蒽环类抗生素诱导的心脏毒性的基因组易感性。
Pharmacogenomics. 2021 Jan;22(1):41-54. doi: 10.2217/pgs-2020-0104. Epub 2021 Jan 15.
5
Possible Susceptibility Genes for Intervention against Chemotherapy-Induced Cardiotoxicity.干预化疗引起的心脏毒性的可能易感性基因。
Oxid Med Cell Longev. 2020 Oct 13;2020:4894625. doi: 10.1155/2020/4894625. eCollection 2020.
6
Association of GSTM1 null variant with anthracycline-related cardiomyopathy after childhood cancer-A Children's Oncology Group ALTE03N1 report.GSTM1 缺失变异与儿童癌症后蒽环类药物相关心肌病的关联:儿童肿瘤学组 ALTE03N1 报告。
Cancer. 2020 Sep 1;126(17):4051-4058. doi: 10.1002/cncr.32948. Epub 2020 May 15.
7
Development of a CART Model to Predict the Synthesis of Cardiotoxic Daunorubicinol in Heart Tissue Samples From Donors With and Without Down Syndrome.开发一种CART模型,用于预测患有和未患有唐氏综合征的供体心脏组织样本中心脏毒性柔红霉素醇的合成。
J Pharm Sci. 2016 Jun;105(6):2005-2008. doi: 10.1016/j.xphs.2016.03.013. Epub 2016 Apr 23.
8
The Use of Chemical-Chemical Interaction and Chemical Structure to Identify New Candidate Chemicals Related to Lung Cancer.利用化学-化学相互作用和化学结构来鉴定与肺癌相关的新候选化学物质。
PLoS One. 2015 Jun 5;10(6):e0128696. doi: 10.1371/journal.pone.0128696. eCollection 2015.
9
Patient-Specific Pluripotent Stem Cells in Doxorubicin Cardiotoxicity: A New Window Into Personalized Medicine.多柔比星心脏毒性中的患者特异性多能干细胞:个性化医疗的新窗口。
Prog Pediatr Cardiol. 2014 Dec 1;37(1-2):23-27. doi: 10.1016/j.ppedcard.2014.10.006.
10
Interindividual variability in the cardiac expression of anthracycline reductases in donors with and without Down syndrome.患有和未患有唐氏综合征的供体中蒽环类还原酶心脏表达的个体间变异性。
Pharm Res. 2014 Jul;31(7):1644-55. doi: 10.1007/s11095-013-1267-1. Epub 2014 Feb 22.